The following LinkedIn post is a very interesting one (altho one that is probably better suited to kpax's sciency thread but is relevant to our CDH17 trial in a sense). I'm not sure if it means the Chinese are being clever or sneaky or both, with the use of what is essentially a chemo drug in the pre-infusion regime for their Satri-cel trial.
I think the discussion is worthy of posting, seeing the results of the trial are being hailed as a first for CAR-T in solid tumours and @KrushingIt has highlighted the trial a few times in the past months, noting that CHM-2101 is 3rd-gen CAR-T. I'm inclined to think this bodes well for CHM if our trial doesn't incorporate the use of Nab-paclitaxel and is more akin to "pure, unadulterated" CAR-T... or alternatively, our CAR-T results could be further enhanced by using it.
CHM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)